Identification of a ZU5 and Death Domain-containing Inhibitor of NF-κB
Jun Zhang,Liang-Guo Xu,Ke-Jun Han,Hong-Bing Shu
DOI: https://doi.org/10.1074/jbc.m310737200
IF: 5.485
2004-01-01
Journal of Biological Chemistry
Abstract:The transcription factor NF-κB plays important roles in inflammation and cell survival. NF-κB is composed of homodimeric and heterodimeric complexes of Rel/NF-κB family members, including p65 (RelA), c-Rel (Rel), RelB, NF-κB1/p50, and NF-κB2/p52. Here we report the identification and characterization of a novel ZU5 and death domain-containing protein designated ZUD. In reporter gene assays, overexpression of ZUD inhibited NF-κB-dependent transcription induced by both tumor necrosis factor (TNF) and interleukin-1 and their downstream signaling proteins. Gel shift assays indicated that the overexpression of ZUD inhibited binding of NF-κB to its target sequence. ZUD is a cytoplasmic protein, and coimmunoprecipitation assays indicated that ZUD interacted with the NF-κB subunit p105 and transactivator p65. Consistent with its role in inhibition of NF-κB-dependent transcription, ZUD sensitized cells to apoptosis induced by TNF and the TNF-related apoptosis-inducing ligand (TRAIL). Our findings suggest that ZUD is an inhibitor of NF-κB activation and that this protein may provide an alternative regulatory mechanism for NF-κB-mediated transcription. The transcription factor NF-κB plays important roles in inflammation and cell survival. NF-κB is composed of homodimeric and heterodimeric complexes of Rel/NF-κB family members, including p65 (RelA), c-Rel (Rel), RelB, NF-κB1/p50, and NF-κB2/p52. Here we report the identification and characterization of a novel ZU5 and death domain-containing protein designated ZUD. In reporter gene assays, overexpression of ZUD inhibited NF-κB-dependent transcription induced by both tumor necrosis factor (TNF) and interleukin-1 and their downstream signaling proteins. Gel shift assays indicated that the overexpression of ZUD inhibited binding of NF-κB to its target sequence. ZUD is a cytoplasmic protein, and coimmunoprecipitation assays indicated that ZUD interacted with the NF-κB subunit p105 and transactivator p65. Consistent with its role in inhibition of NF-κB-dependent transcription, ZUD sensitized cells to apoptosis induced by TNF and the TNF-related apoptosis-inducing ligand (TRAIL). Our findings suggest that ZUD is an inhibitor of NF-κB activation and that this protein may provide an alternative regulatory mechanism for NF-κB-mediated transcription. The NF-κB/Rel family of transcription factors play critical roles in the regulation of immune responses, inflammation, apoptosis, and cell survival through induction of a large set of downstream genes, including cytokines, chemokines, adhesion molecules, and effectors (1Siebenlist U. Franzoso G. Brown K. Annu. Rev. Cell Biol. 1994; 10: 405-445Crossref PubMed Scopus (2003) Google Scholar, 2Baeuerle P.A. Cell. 1998; 95: 729-731Abstract Full Text Full Text PDF PubMed Scopus (416) Google Scholar, 3Barkett M. Gilmore T.D. Oncogene. 1999; 18: 6910-6924Crossref PubMed Scopus (1064) Google Scholar, 4Karin M. Ben-Neriah Y. Annu. Rev. Immunol. 2000; 18: 621-663Crossref PubMed Scopus (4024) Google Scholar, 5Baldwin A.S. J. Clin. Investig. 2001; 107: 241-246Crossref PubMed Scopus (1182) Google Scholar, 6Ghosh S. Karin M. Cell. 2002; 109: S81-S96Abstract Full Text Full Text PDF PubMed Scopus (3260) Google Scholar, 7Karin M. Lin A. Nat. Immunol. 2002; 3: 221-222Crossref PubMed Scopus (2422) Google Scholar). Five members of this family have been identified in vertebrates, including p65 (RelA), c-Rel (Rel), RelB, NF-κB1/p50, and NF-κB2/p52. All of these proteins share a conserved 300-amino acid region known as the Rel homology domain, which is responsible for DNA binding, dimerization, and nuclear translocation of NF-κB. These proteins bind DNA as homo- and hetero-dimers. Two of the active subunits of NF-κB, p50 and p52, are derived from the N-terminal domains of their precursor molecules, p105 and p100, respectively, via post-translational processing of the C-terminal ankyrin repeat-containing domains by the 26 S proteasome (1Siebenlist U. Franzoso G. Brown K. Annu. Rev. Cell Biol. 1994; 10: 405-445Crossref PubMed Scopus (2003) Google Scholar, 2Baeuerle P.A. Cell. 1998; 95: 729-731Abstract Full Text Full Text PDF PubMed Scopus (416) Google Scholar). The major cellular form of NF-κB is a heterodimer consisting of the DNA binding subunit p50 and the transactivator p65. Normally, NF-κB is retained in the cytoplasm of unstimulated cells through association with its inhibitor IκB. Upon stimulation by various NF-κB activating signals, IκB is phosphorylated and degraded through an ubiquitin-dependent process. This process frees NF-κB, which is then translocated into the nucleus to activate transcription of its target genes (1Siebenlist U. Franzoso G. Brown K. Annu. Rev. Cell Biol. 1994; 10: 405-445Crossref PubMed Scopus (2003) Google Scholar, 2Baeuerle P.A. Cell. 1998; 95: 729-731Abstract Full Text Full Text PDF PubMed Scopus (416) Google Scholar, 3Barkett M. Gilmore T.D. Oncogene. 1999; 18: 6910-6924Crossref PubMed Scopus (1064) Google Scholar, 4Karin M. Ben-Neriah Y. Annu. Rev. Immunol. 2000; 18: 621-663Crossref PubMed Scopus (4024) Google Scholar, 5Baldwin A.S. J. Clin. Investig. 2001; 107: 241-246Crossref PubMed Scopus (1182) Google Scholar, 6Ghosh S. Karin M. Cell. 2002; 109: S81-S96Abstract Full Text Full Text PDF PubMed Scopus (3260) Google Scholar, 7Karin M. Lin A. Nat. Immunol. 2002; 3: 221-222Crossref PubMed Scopus (2422) Google Scholar). The transcriptional activity of NF-κB is also modulated by regulation of p65 phosphorylation (4Karin M. Ben-Neriah Y. Annu. Rev. Immunol. 2000; 18: 621-663Crossref PubMed Scopus (4024) Google Scholar, 6Ghosh S. Karin M. Cell. 2002; 109: S81-S96Abstract Full Text Full Text PDF PubMed Scopus (3260) Google Scholar). TNF 1The abbreviations used are: TNF, tumor necrosis factor; DD, death domain; EST, expressed sequence tag; FADD, Fas-associated DD protein; IFN, interferon; IKK, inhibitory κB kinase; IL-1, interleukin 1; IRF-1, interferon response factor 1; NF-κB, nuclear factor κB; PBS, phosphate-buffered saline; RIP, receptor-interacting protein; SINK, p65-interacting inhibitor of NF-κB; TNF-R1, TNF receptor 1; TRAF, TNF receptor-associated factor; TRADD, tumor necrosis factor receptor-associated DD protein; TRAIL, TNF-related apoptosis-inducing ligand; UNC5H, Caenorhabditis elegans UNC-5 homolog; X-gal, 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside; ZUD, ZU5 and death domain-containing protein. 1The abbreviations used are: TNF, tumor necrosis factor; DD, death domain; EST, expressed sequence tag; FADD, Fas-associated DD protein; IFN, interferon; IKK, inhibitory κB kinase; IL-1, interleukin 1; IRF-1, interferon response factor 1; NF-κB, nuclear factor κB; PBS, phosphate-buffered saline; RIP, receptor-interacting protein; SINK, p65-interacting inhibitor of NF-κB; TNF-R1, TNF receptor 1; TRAF, TNF receptor-associated factor; TRADD, tumor necrosis factor receptor-associated DD protein; TRAIL, TNF-related apoptosis-inducing ligand; UNC5H, Caenorhabditis elegans UNC-5 homolog; X-gal, 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside; ZUD, ZU5 and death domain-containing protein. is one of the major proinflammatory cytokines that activate NF-κB (8Locksley R.M. Killeen N. Lenardo M.J. Cell. 2001; 104: 487-501Abstract Full Text Full Text PDF PubMed Scopus (2936) Google Scholar). Upon TNF stimulation, TNF receptor 1 (TNF-R1), which contains a cytoplasmic death domain (DD), trimerizes and recruits the downstream DD-containing protein TRADD (TNF-receptor-associated death domain) to the receptor signaling complex (9Hsu H. Xiong J. Goeddel D.V. Cell. 1995; 81: 495-504Abstract Full Text PDF PubMed Scopus (1721) Google Scholar, 10Hsu H. Shu H.B. Pan M.G. Goeddel D.V. Cell. 1996; 84: 299-308Abstract Full Text Full Text PDF PubMed Scopus (1719) Google Scholar). TRADD then functions as an adaptor to recruit several downstream proteins, including FADD (Fas-associated death domain), TRAF2 (TNF receptor-associated factor 2), and RIP (receptor-interacting protein) to the TNF-R1 signaling complex (9Hsu H. Xiong J. Goeddel D.V. Cell. 1995; 81: 495-504Abstract Full Text PDF PubMed Scopus (1721) Google Scholar, 10Hsu H. Shu H.B. Pan M.G. Goeddel D.V. Cell. 1996; 84: 299-308Abstract Full Text Full Text PDF PubMed Scopus (1719) Google Scholar, 11Hsu H. Huang J. Shu H.B. Baichwal V. Goeddel D.V. Immunity. 1996; 4: 387-396Abstract Full Text Full Text PDF PubMed Scopus (964) Google Scholar, 12Shu H.B. Takeuchi M. Goeddel D.V. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 13973-13978Crossref PubMed Scopus (363) Google Scholar). Although FADD is critically involved in TNF-R1-mediated apoptosis, TRAF2 and RIP recruit IKK (IκB kinase) to the TNF-R1 complex (13Devin A. Cook A. Lin Y. Rodriguez Y. Kelliher M. Liu Z. Immunity. 2000; 12: 419-429Abstract Full Text Full Text PDF PubMed Scopus (353) Google Scholar, 14Zhang S.Q. Kovalenko A. Cantarella G. Wallach D. Immunity. 2000; 12: 301-311Abstract Full Text Full Text PDF PubMed Scopus (391) Google Scholar). IKK contains three subunits, the catalytic subunits IKKα and IKKβ and the regulatory subunit IKKγ (6Ghosh S. Karin M. Cell. 2002; 109: S81-S96Abstract Full Text Full Text PDF PubMed Scopus (3260) Google Scholar). Once IKK is recruited to the TNF-R1 complex, it is activated and subsequently leads to IκB phosphorylation and NF-κB activation (6Ghosh S. Karin M. Cell. 2002; 109: S81-S96Abstract Full Text Full Text PDF PubMed Scopus (3260) Google Scholar, 7Karin M. Lin A. Nat. Immunol. 2002; 3: 221-222Crossref PubMed Scopus (2422) Google Scholar). Several members of the TNF receptor family contain a conserved DD that is essential for the NF-κB activation and apoptosis induced by these receptors (15Ashkenazi A. Dixit V.M. Science. 1998; 281: 1305-1308Crossref PubMed Scopus (5085) Google Scholar). The DD is also found in several cytoplasmic adapter proteins, including TRADD, FADD, and RIP, and the NF-κB subunits p105 and p100 (15Ashkenazi A. Dixit V.M. Science. 1998; 281: 1305-1308Crossref PubMed Scopus (5085) Google Scholar, 16Chinnaiyan A.M. O'Rourke K. Tewari M. Dixit V.M. Cell. 1995; 81: 505-512Abstract Full Text PDF PubMed Scopus (2144) Google Scholar, 17Boldin M.P. Varfolomeev E.E. Pancer Z. Mett I.L. Camonis J.H. Wallach D. J. Biol. Chem. 1995; 270: 7795-7798Abstract Full Text Full Text PDF PubMed Scopus (937) Google Scholar, 18Stanger B.Z. Leder P. Lee T.H. Kim E. Seed B. Cell. 1995; 81: 513-523Abstract Full Text PDF PubMed Scopus (853) Google Scholar, 19Beinke S. Belich M.P. Ley S.C. J. Biol. Chem. 2002; 277: 24162-24168Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar, 20Wang Y. Cui H. Schroering A. Ding J.L. Lane W.S. McGill G. Fisherk D.E. Ding H.F. Nat. Cell Biol. 2002; 4: 888-893Crossref PubMed Scopus (54) Google Scholar). The death domain exerts its effects via self-association and/or interaction with death domain of other proteins (15Ashkenazi A. Dixit V.M. Science. 1998; 281: 1305-1308Crossref PubMed Scopus (5085) Google Scholar). Here we report the cloning and characterization of a novel DD-containing protein designated ZUD (ZU5 and death domain-containing protein). In addition to the C-terminal DD, ZUD also contains an N-terminal ZU5 domain that is found in the cytoplasmic domains of UNC5H receptor family members (21Hong K. Hinck L. Nishiyama M. Poo M.P. Tessier-Lavigne M. Stein E. Cell. 1999; 97: 927-941Abstract Full Text Full Text PDF PubMed Scopus (567) Google Scholar, 22Leonardo E.D. Hinck L. Masu M. Keino-Masu K. Ackerman S.L. Tessier-Lavigne M. Nature. 1997; 386: 833-836Crossref PubMed Scopus (420) Google Scholar, 23Ackerman S.L. Kozak L.P. Przyborski S.A. Rund L.A. Boyer B.B. Knowles B.B. Nature. 1997; 386: 838-842Crossref PubMed Scopus (311) Google Scholar, 24Llambi F. Causeret F. Bloch-Gallego E. Mehlen P. EMBO J. 2001; 20: 2715-2722Crossref PubMed Scopus (270) Google Scholar, 25Tanikawa C. Matsuda K. Nakanashi H. Fukuda S. Nakamura Y. Arakawa H. Nat. Cell Biol. 2003; 5: 216-223Crossref PubMed Scopus (152) Google Scholar, 26Thiebault K. Mazelin L. Pays L. Llambi F. Joly M.O. Scoazec J.Y. Saurin J.C. Romeo G. Mehlen P. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 4173-4178Crossref PubMed Scopus (166) Google Scholar). Our data demonstrate that ZUD is a cytoplasmic protein associated with p105 and p65 and inhibits NF-κB-dependent transcription. Reagents—The ZUD EST clone (Research Genetics, Huntsville, TN), the recombinant human TNF, IL-1, and IFN-γ (R & D Systems Inc., Minneapolis, MN), the monoclonal antibodies against FLAG (Sigma), Myc (Santa Cruz Biotechnology, Santa Cruz, CA), hemagglutinin epitopes (Covance, Berkeley, CA), and the goat polyclonal antibody against p65 and the rabbit polyclonal antibody against p50 and IκBα (Santa Cruz Biotechnology, Santa Cruz, CA) were purchased from the indicated manufacturers. Recombinant soluble TRAIL was produced in our laboratory (27Hu W.H. Johnson H. Shu H.B. J. Biol. Chem. 1999; 275: 10838-10844Abstract Full Text Full Text PDF Scopus (255) Google Scholar). Human embryonic kidney 293 cells were obtained from the American Type Culture Collection (Manassas, VA). Constructs—Expression plasmids for TNF-R1, TRAF2, TRAF6, IKK-β, p65, p50, and IκBα (Dr. David Goeddel) and the NF-κB (Dr. Gary Johnson) and IRF-1 (Dr. Uli Schindler) luciferase reporter constructs were provided by the indicated investigators. Mammalian expression plasmids for Myc-tagged p105 and its deletion mutants and for hemagglutinin- or FLAG-tagged ZUD and its deletion mutants were constructed by PCR amplification of the corresponding cDNA fragments and subsequent cloning into a cytomegalovirus promoter-based vector. Mammalian expression plasmid for SINK was described previously (28Wu M. Xu L. Zhai Z. Shu H.B. J. Biol. Chem. 2003; 278: 27072-27079Abstract Full Text Full Text PDF PubMed Scopus (95) Google Scholar). Northern Blot Hybridization—Human multiple tissue mRNA blots were purchased from Clontech (Palo Alto, CA). The cDNA probe was an ∼1.6-kb fragment corresponding to the coding sequence of amino acids 1-518 of ZUD. The hybridization was performed with the radiolabeled ZUD cDNA probe in rapid hybridization buffer (Clontech, Palo Alto, CA) under high stringency conditions. Cell Transfection and Reporter Gene Assays—293 cells (∼2 × 105) were seeded on 6-well (35-mm) dishes and transfected the following day by the standard calcium phosphate precipitation method (29Sambrook J. Fritch E.F. Maniatis T. Molecular Cloning: A Laboratory Manual.2nd Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY1989Google Scholar). Within the same experiment, each transfection was performed in triplicate, and, where necessary, an empty control plasmid was added to ensure that each transfection received the same amount of total DNA. To normalize for transfection efficiency, 0.3 μg of a Rous sarcoma virus β-galactosidase plasmid was added to each transfection. Luciferase reporter assays were performed using a luciferase assay kit (BD PharMingen) and following the manufacturer's protocols. β-galactosidase activity was measured using the Galacto-Light chemiluminescent kit (Tropix, Bedford, MA). Luciferase activities were normalized on the basis of β-galactosidase activities. Co-immunoprecipitation and Western Blot Analysis—Transfected 293 cells from each 100-mm dish were lysed in 1 ml of lysis buffer (20 mm Tris, pH 7.5, 150 mm NaCl, 1% Triton X-100, 1 mm EDTA, 10 μg/ml aprotinin, 10 μg/ml leupeptin, and 1 mm phenylmethylsulfonyl fluoride). For each immunoprecipitation, a 0.4-ml aliquot of lysate was incubated with 0.5 μg of the indicated monoclonal antibody or control mouse IgG and 25 μl of a 1:1 slurry of GammaBind G Plus-Sepharose (Amersham Biosciences) for at least 1 h. The Sepharose beads were washed three times with 1 ml of lysis buffer containing 500 mm NaCl. The precipitates were fractionated on SDS-PAGE, and subsequent Western blot analyses were performed as described (27Hu W.H. Johnson H. Shu H.B. J. Biol. Chem. 1999; 275: 10838-10844Abstract Full Text Full Text PDF Scopus (255) Google Scholar, 28Wu M. Xu L. Zhai Z. Shu H.B. J. Biol. Chem. 2003; 278: 27072-27079Abstract Full Text Full Text PDF PubMed Scopus (95) Google Scholar, 29Sambrook J. Fritch E.F. Maniatis T. Molecular Cloning: A Laboratory Manual.2nd Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY1989Google Scholar, 30Chen D. Li X. Zhai Z. Shu H.B. J. Biol. Chem. 2002; 277: 15985-15991Abstract Full Text Full Text PDF PubMed Scopus (55) Google Scholar). Immunofluorescent Staining—293 cells cultured on glass coverslips were sequentially plunged into methanol at -20 °C for 10 min. The cells were rehydrated in PBS, blocked with 1% bovine serum albumin in PBS for 30 min, and stained with a monoclonal anti-FLAG antibody (2 μg/ml) in blocking buffer for 1 h at room temperature. The cells were rinsed with PBS and stained with fluorescein isothiocyanate-conjugated goat anti-mouse IgG (1:200 dilution) for 45 min at room temperature. The cells were then rinsed with PBS containing Hoechst 33342 and mounted in Prolong Antifade (Molecular Probes, Eugene, OR). The cells were observed with a Leica DMR/XA immunofluorescent microscope using a 40× plan objective. Apoptosis Assays—β-Galactosidase co-transfection assays for determination of cell death were performed as described previously (9Hsu H. Xiong J. Goeddel D.V. Cell. 1995; 81: 495-504Abstract Full Text PDF PubMed Scopus (1721) Google Scholar, 10Hsu H. Shu H.B. Pan M.G. Goeddel D.V. Cell. 1996; 84: 299-308Abstract Full Text Full Text PDF PubMed Scopus (1719) Google Scholar, 11Hsu H. Huang J. Shu H.B. Baichwal V. Goeddel D.V. Immunity. 1996; 4: 387-396Abstract Full Text Full Text PDF PubMed Scopus (964) Google Scholar, 28Wu M. Xu L. Zhai Z. Shu H.B. J. Biol. Chem. 2003; 278: 27072-27079Abstract Full Text Full Text PDF PubMed Scopus (95) Google Scholar, 31Shu H.B. Halpins D.R. Goeddel D.V. Immunity. 1997; 6: 751-763Abstract Full Text Full Text PDF PubMed Scopus (366) Google Scholar). Briefly, 293 cells (∼2 × 105) were seeded on 6-well (35-mm) dishes and transfected the following day with 0.1 μg of a cytomegalovirus β-galactosidase plasmid and 2 μg of an expression plasmid for ZUD or an empty control plasmid. Approximately 36 h after transfection the cells were stained with X-gal. The numbers of surviving blue cells from five representative viewing fields were determined microscopically. Data shown are averages and standard deviations of one representative experiment in which each transfection has been performed in triplicate. Electrophoretic Mobility Shift Assay—An electrophoretic mobility shift assay was performed as described previously (27Hu W.H. Johnson H. Shu H.B. J. Biol. Chem. 1999; 275: 10838-10844Abstract Full Text Full Text PDF Scopus (255) Google Scholar, 28Wu M. Xu L. Zhai Z. Shu H.B. J. Biol. Chem. 2003; 278: 27072-27079Abstract Full Text Full Text PDF PubMed Scopus (95) Google Scholar, 32Xu L.G. Wu M. Hu J. Zhai Z. Shu H.B. J. Leukocyte Biol. 2002; 72: 410-416PubMed Google Scholar). Briefly, 293 cells (∼2 × 106) cells were transfected with 10 μg of empty control plasmid or an expression plasmid for ZUD or SINK. Twenty-four hours after transfection, the cells were treated with TNF (20 ng/ml) for 30 min. The cells were harvested and incubated in 500 μl of Buffer A (10 mm Hepes, 10 mm NaCl, 5 mm EDTA, 1.5 mm MgCl2, 10 μg/ml aprotinin and leupeptin, 2 mm dithiothreitol, and 1 mm phenylmethylsulfonyl fluoride, pH 7.8) at 4 °C for 10 min. Five hundred microliters of Buffer B (Buffer A plus 1.2% Nonidet P-40) was added, and the sample was mixed vigorously for 10 s. The pellet was spun down, washed with buffer A, and resuspended in 4.5 μl of Buffer C (Buffer A plus 10% glycerol). After the addition of 5 μl of 4.1 m NaCl and incubation at 4 °C for 30 min, the sample was centrifuged, and the nuclear extract in the supernatant was quantified with a Bio-Rad protein assay kit. The NF-κB target oligonucleotide 5′-GGGGACTTTCCC-3′ (Santa Cruz Biotechnology), was labeled with [32P]ATP by T4 DNA kinase and incubated with 20 μg of nuclear extract and 0.8 μg poly dI-dC in binding buffer (20 mm Tris, 50 mm KCl, 1 mm EDTA, 1 mm dithiothreitol, 0.1% Nonidet P-40, and 5% glycerol, pH 7.5) at room temperature for 15 min. The mixture was fractionated in 5% acrylamide gel prepared in 0.5× Tris borate-EDTA. The gel was dried and subjected to autoradiography. Identification and Cloning of ZUD—To identify a potential DD-containing protein, we searched the GenBank™ EST databases using the tBLASTn program. This search identified multiple human EST clones that encode a novel DD-containing protein, which was designated ZUD. The longest EST clone (GenBank™ accession number BI762014) encodes the full-length human ZUD protein because it contains an in-frame stop codon 5′ of the putative ATG start codon and a poly(A) signal sequence at the 3′-end (data not shown). Sequence analysis indicated that human ZUD cDNA encodes a 518 amino acid protein (Fig. 1A). BLAST searches of the GenBank™ databases indicated that human ZUD shares ∼83% sequence identity with its mouse ortholog at the amino acid level. Structural analysis indicated that ZUD contains an N-terminal ZU5 domain (aa108-186) (a functionally unknown domain found in ZO-1 and UNC5H receptors), a middle leucine zipper motif (aa 249-270), and a C-terminal death domain (aa 423-491) (Fig. 1A). ZUD is mostly homologous to the cytoplasmic fragments of the UNC5H receptor family members, which also contain a ZU5 domain and a death domain (21Hong K. Hinck L. Nishiyama M. Poo M.P. Tessier-Lavigne M. Stein E. Cell. 1999; 97: 927-941Abstract Full Text Full Text PDF PubMed Scopus (567) Google Scholar, 22Leonardo E.D. Hinck L. Masu M. Keino-Masu K. Ackerman S.L. Tessier-Lavigne M. Nature. 1997; 386: 833-836Crossref PubMed Scopus (420) Google Scholar, 23Ackerman S.L. Kozak L.P. Przyborski S.A. Rund L.A. Boyer B.B. Knowles B.B. Nature. 1997; 386: 838-842Crossref PubMed Scopus (311) Google Scholar, 24Llambi F. Causeret F. Bloch-Gallego E. Mehlen P. EMBO J. 2001; 20: 2715-2722Crossref PubMed Scopus (270) Google Scholar, 25Tanikawa C. Matsuda K. Nakanashi H. Fukuda S. Nakamura Y. Arakawa H. Nat. Cell Biol. 2003; 5: 216-223Crossref PubMed Scopus (152) Google Scholar, 26Thiebault K. Mazelin L. Pays L. Llambi F. Joly M.O. Scoazec J.Y. Saurin J.C. Romeo G. Mehlen P. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 4173-4178Crossref PubMed Scopus (166) Google Scholar). The overall similarity between ZUD and the cytoplasmic domains of UNC5H receptors is ∼40%. Northern blot analysis indicated that ZUD is expressed in pancreas, kidney, and liver as transcripts of ∼3 and ∼4kb respectively (Fig. 1B). ZUD mRNA is barely detectable in other examined tissues, including heart, brain, placenta, lung, skeletal muscle, spleen, thymus, prostate, uterus, testis, small intestine, colon, and peripheral blood leukocytes (Fig. 1B). Analysis of available sequences in the GenBank™ databases (cDNAs, ESTs, and genomic sequences) suggests that the more abundant ∼3 kb transcript represents the cDNA sequence we obtained. Because this sequence contains a 5′ in-frame stop codon and no splicing or poly(A) signal variants were identified by the GenBank™ data base searches, the ∼4 kb transcript may represent an alternative splicing form in which additional 5′-untranslated region sequence is included. ZUD Inhibits NF-κB-dependent Transcription—Because ZUD contains a DD, we determined whether ZUD has a role in apoptosis. Transient transfection experiments indicated that overexpression of ZUD could not induce apoptosis or inhibit death receptor-induced apoptosis (data not shown). Because many DD-containing proteins are involved in NF-κB activation and the NF-κB subunits p105 and p100 themselves contain DDs, we determined whether ZUD has a role in NF-κB activation. In reporter gene assays, overexpression of ZUD did not activate NF-κB but significantly inhibited NF-κB activation induced by overexpression of TNF-R1, TRAF2, TRAF6, IKKβ, and p65 (Fig. 2A). Moreover, ZUD could also inhibit NF-κB activation triggered by TNF and IL-1 stimulation (Fig. 2B). In contrast, ZUD did not inhibit IFN-γ-induced IRF-1 activation (Fig. 2C), suggesting that ZUD specifically inhibits TNF and IL-1 triggered NF-κB activation. ZUD Is a Cytoplasmic Protein and Inhibits NF-κB Binding to Its Target Sequence—Because ZUD inhibits p65-mediated transcription in our reporter assays (Fig. 2A), we reasoned that ZUD acts at a downstream step of the NF-κB activation pathways. To determine the potential mechanism, we examined the cellular localization of ZUD by immunofluorescent microscopy. These experiments indicated that ZUD was mostly localized in the cytoplasm and that this localization was not changed by TNF treatment (Fig. 3A). We next determined whether ZUD affects NF-κB transport into the nucleus and binding to its target sequences. Using gel shift assays, we found that ZUD inhibited TNF-induced NF-κB binding to a conserved target sequence (Fig. 3B). In these assays, a control protein, SINK, did not inhibit TNF-induced NF-κB DNA binding activity (Fig. 3B). These data suggest that ZUD functions in the cytoplasm to inhibit NF-κB binding to its target sequence. ZUD Is Associated with p105 and p65—Because ZUD inhibits NF-κB DNA binding activity, we determined whether this inhibitory effect is mediated by physical association between ZUD and NF-κB or IκB components. We co-transfected ZUD and p50, p65, p105, IκBα, IKKα, or IKKβ into 293 cells and performed co-immunoprecipitation experiments. The results indicated that ZUD interacted with p65 and p105 but not with p50, IκBα, IKKα, orIKKβ (Fig. 4, A and B). Consistent with the fact that ZUD interacted with p105 but not p50, domain-mapping experiments indicated that ZUD interacted with the C terminus (aa 535-969) (equivalent to IκBγ) but not the N terminus (aa 1-434) (equivalent to p50) of p105 (Fig. 4B). To determine which domain of ZUD is responsible for its interaction with p105 and p65, we made several deletion mutants of ZUD (Fig. 5A). Transient transfection and co-immunoprecipitation experiments indicated that the middle region containing the leucine zipper motif of ZUD, aa 186-400, is required and sufficient for interaction with p105 and p65 (Fig. 5). ZUD Sensitizes Cells to TNF- and TRAIL-induced Apoptosis—NF-κB promotes cell survival through transcriptional induction of anti-apoptotic genes (2Baeuerle P.A. Cell. 1998; 95: 729-731Abstract Full Text Full Text PDF PubMed Scopus (416) Google Scholar, 3Barkett M. Gilmore T.D. Oncogene. 1999; 18: 6910-6924Crossref PubMed Scopus (1064) Google Scholar, 7Karin M. Lin A. Nat. Immunol. 2002; 3: 221-222Crossref PubMed Scopus (2422) Google Scholar, 34Wang C.Y. Mayo M.W. Korneluk R.G. Goeddel D.V. Baldwin Jr., A.S. Science. 1998; 281: 1680-1683Crossref PubMed Scopus (2553) Google Scholar, 35Zong W.X. Edelstein L.C. Chen C. Bash J. Gelinas C. Genes Dev. 1999; 13: 382-387Crossref PubMed Scopus (638) Google Scholar, 36Micheau O. Lens S. Gaide O. Alevizopoulos K. Tschopp J. Mol. Cell. Biol. 2001; 21: 5299-5305Crossref PubMed Scopus (679) Google Scholar). Because ZUD inhibits NF-κB-dependent transcription, we determined whether ZUD affects NF-κB-dependent cell survival. We transfected 293 cells with an expression plasmid for ZUD and examined its effect on TNF- and TRAIL-induced apoptosis. The results indicated that overexpression of ZUD significantly sensitized 293 cells to TNF- and TRAIL-induced apoptosis (Fig. 6). In an attempt to clone novel DD-containing proteins, we isolated ZUD by searching human EST databases. ZUD contained a conserved ZU5 domain, a middle leucine zipper motif, and a C-terminal DD. Analysis of the amino acid sequence of ZUD suggests that it is homologous to the cytoplasmic domains of a group of netrin-1 receptors, UNC5H1-4 (21Hong K. Hinck L. Nishiyama M. Poo M.P. Tessier-Lavigne M. Stein E. Cell. 1999; 97: 927-941Abstract Full Text Full Text PDF PubMed Scopus (567) Google Scholar, 22Leonardo E.D. Hinck L. Masu M. Keino-Masu K. Ackerman S.L. Tessier-Lavigne M. Nature. 1997; 386: 833-836Crossref PubMed Scopus (420) Google Scholar, 23Ackerman S.L. Kozak L.P. Przyborski S.A. Rund L.A. Boyer B.B. Knowles B.B. Nature. 1997; 386: 838-842Crossref PubMed Scopus (311) Google Scholar, 24Llambi F. Causeret F. Bloch-Gallego E. Mehlen P. EMBO J. 2001; 20: 2715-2722Crossref PubMed Scopus (270) Google Scholar, 25Tanikawa C. Matsuda K. Nakanashi H. Fukuda S. Nakamura Y. Arakawa H. Nat. Cell Biol. 2003; 5: 216-223Crossref PubMed Scopus (152) Google Scholar, 26Thiebault K. Mazelin L. Pays L. Llambi F. Joly M.O. Scoazec J.Y. Saurin J.C. Romeo G. Mehlen P. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 4173-4178Crossref PubMed Scopus (166) Google Scholar). These receptors were initially proposed as mediators of the chemo-repulsive effects of netrin-1 on specific axons (22Leonardo E.D. Hinck L. Masu M. Keino-Masu K. Ackerman S.L. Tessier-Lavigne M. Nature. 1997; 386: 833-836Crossref PubMed Scopus (420) Google Scholar). Although UNC5H receptors are highly expressed in specific neurons during the development of the nervous system in adults, their expression can also be detected in thyroid, kidney, ovary, uterus, stomach, colon, lung, spleen, bladder, and breast tissues (23Ackerman S.L. Kozak L.P. Przyborski S.A. Rund L.A. Boyer B.B. Knowles B.B. Nature. 1997; 386: 838-842Crossref PubMed Scopus (311) Google Scholar). These observations suggest a role for these receptors away from the neuronal guidance system. Recently, it has been shown that these receptors, when unbound to their ligand, induce apoptosis (24Llambi F. Causeret F. Bloch-Gallego E. Mehlen P. EMBO J. 2001; 20: 2715-2722Crossref PubMed Scopus (270) Google Scholar). One of the UNC5H genes, UNC5H2/B, was recently shown to be a direct transcriptional target of the tumor suppressor p53 and to mediate the proapoptotic activity of p53 (25Tanikawa C. Matsuda K. Nakanashi H. Fukuda S. Nakamura Y. Arakawa H. Nat. Cell Biol. 2003; 5: 216-223Crossref PubMed Scopus (152) Google Scholar). In addition, human UNC5H1, UNC5H2, and UNC5H3 are down-regulated in multiple cancers, and overexpression of these receptors inhibits anchorage-independent growth and invasion of tumor cells (26Thiebault K. Mazelin L. Pays L. Llambi F. Joly M.O. Scoazec J.Y. Saurin J.C. Romeo G. Mehlen P. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 4173-4178Crossref PubMed Scopus (166) Google Scholar). Because ZUD is undetectable in the brain, it may have no role in UNC5H-mediated chemo-repulsive effects. However, it is possible that ZUD may be involved in other UNC5H-mediated effects. In transient transfection and co-immunoprecipitation experiments, we found that ZUD could interact with UNC5H2 in 293 cells (data not shown), pointing to the possibility that they are functionally connected. It has been suggested that UNC5H induces apoptosis when it is not bound with its ligand (24Llambi F. Causeret F. Bloch-Gallego E. Mehlen P. EMBO J. 2001; 20: 2715-2722Crossref PubMed Scopus (270) Google Scholar). Our future studies will investigate whether ZUD is involved in this process. Overexpression of ZUD inhibited TNF- and IL1-triggered NF-κB activation, but not IFN-γ-triggered IRF-1 activation, suggesting that ZUD is a specific inhibitor of the NF-κB activation pathways (Fig. 2). In addition, overexpression of ZUD also inhibited TNF-R1-, TRAF2-, TRAF6-, IKKβ-, and p65-induced NF-κB activation (Fig. 2). In gel shift assays, overexpression of ZUD inhibited TNF-induced NF-κB binding to its target sequence (Fig. 3B). Because ZUD is primarily a cytoplasmic protein (Fig. 3A), our original hypothesis was that ZUD might act by retaining NF-κB, especially the p65 subunit, in the cytoplasm. However, immunofluorescent staining experiments indicated that overexpression of ZUD did not block TNF-induced translocation of p65 and p50 to the nucleus (data not shown). Currently, the mechanisms responsible for the inhibitory effects of ZUD are unknown. One of the possibilities is that ZUD affects modification of p65 in the cytoplasm, such as phosphorylation, and this leads to inhibition of NF-κB binding to its target sequence and the subsequent inhibition of NF-κB-mediated transcription. In this context, it has been shown that p65 phosphorylation is important for the full transcription competence of NF-κB (37Naumann M. Scheidereit C. EMBO J. 1994; 13: 4597-4607Crossref PubMed Scopus (325) Google Scholar, 38Neumann M. Grieshammer T. Chuvpilo S. Kneitz B. Lohoff M. Schimpl A. Franza Jr., B.R. Serfling E. EMBO J. 1995; 14: 1991-2004Crossref PubMed Scopus (181) Google Scholar, 39Zhong H Voll R.E. Ghosh S. Mol. Cell. 1998; 1: 661-671Abstract Full Text Full Text PDF PubMed Scopus (1017) Google Scholar, 40Zhong H. SuYang H. Erdjument-Bromage H. Tempst P. Ghosh S. Cell. 1997; 89: 413-424Abstract Full Text Full Text PDF PubMed Scopus (724) Google Scholar, 41Perkins N.D. Felsien L.K. Betts J.C. Leung K. Beach D.H. Nabel G.J. Science. 1997; 275: 523-527Crossref PubMed Scopus (665) Google Scholar). Consistent with its role in inhibiting NF-κB-dependent transcription, ZUD also sensitizes cells to TNF- and TRAIL-induced apoptosis, probably through the inhibition of expression of NF-κB activated anti-apoptotic genes. Taken together, our findings provide evidence that ZUD is a novel NF-κB inhibitor with functional similarity to IκB proteins. Previously, it has been shown that p65 interacts directly with multiple proteins other than the IκB family, including p202 (42Min W. Ghosh S. Lengyel P. Mol. Cell. Biol. 1996; 16: 359-368Crossref PubMed Scopus (142) Google Scholar), CREB-binding protein/p300 (41Perkins N.D. Felsien L.K. Betts J.C. Leung K. Beach D.H. Nabel G.J. Science. 1997; 275: 523-527Crossref PubMed Scopus (665) Google Scholar), Stat 6 (44Shen C.H. Stavnezer J. Mol. Cell. Biol. 1998; 18: 3395-3404Crossref PubMed Google Scholar), TAFII105 (45Yamit-Hezi A. Dikstein R. EMBO J. 1998; 17: 5161-5169Crossref PubMed Scopus (68) Google Scholar), RAI (41Perkins N.D. Felsien L.K. Betts J.C. Leung K. Beach D.H. Nabel G.J. Science. 1997; 275: 523-527Crossref PubMed Scopus (665) Google Scholar), SINK (28Wu M. Xu L. Zhai Z. Shu H.B. J. Biol. Chem. 2003; 278: 27072-27079Abstract Full Text Full Text PDF PubMed Scopus (95) Google Scholar), AO7 (43Yang J.P. Hori M. Sanda T. Okamoto T. J. Biol. Chem. 1999; 274: 15662-15670Abstract Full Text Full Text PDF PubMed Scopus (140) Google Scholar), and BRCA1 (33Asamitsu K. Tetsuka T. Kanazawa S. Okamoto T. J. Biol. Chem. 2003; 278: 26879-26887Abstract Full Text Full Text PDF PubMed Scopus (32) Google Scholar), which either suppress or activate NF-κB. It is possible that these NF-κB-interacting proteins, including ZUD, are involved in a coordinated regulation of its activity in either a tissue-specific or nonspecific manner. We thank Dr. James Hagman for help with the gel shift assays.